Keywords: Blood-Brain Barrier, Cognitive Decline, Cytokines, Gut-Brain Axis, Inflammaging, Mental Health, Microglia, Neuroinflammation
Introduction
The brain has long been regarded as an immunologically privileged organ, separated from systemic immune processes by the restrictive architecture of the blood-brain barrier. This paradigm has undergone fundamental revision over the past three decades. Seminal research established that peripheral immune activation, triggered by infection, injury, metabolic dysfunction, or psychosocial stress, reliably produces a constellation of behavioral changes including fatigue, social withdrawal, anhedonia, cognitive slowing, and altered pain sensitivity. These manifestations, collectively termed “sickness behavior,” were initially interpreted as adaptive responses facilitating recovery; however, sustained or dysregulated immune signaling is increasingly recognized as an etiological driver of a broad range of neuropsychiatric conditions [1-3].
The epidemiological burden of inflammation-associated brain disorders is substantial. Major depressive disorder (MDD), affecting over 280 million individuals globally, is strongly associated with elevated inflammatory biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Neurodegenerative disease, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) are now recognized as harboring neuroinflammatory components that actively accelerate pathological progression. In parallel, the global rise of metabolic diseases such as obesity, type 2 diabetes mellitus, and non-alcoholic fatty liver disease has brought increasing attention to chronic low-grade systemic inflammation and its bidirectional relationship with CNS dysfunction [4-7].
Understanding the neuroimmune interface is a matter of pressing clinical and translational relevance, particularly within the context of longevity medicine and metabolic health optimization. This review provides a comprehensive synthesis of the mechanisms by which peripheral inflammation modulates brain function and behavior, integrating insights from molecular immunology, systems neuroscience, clinical psychiatry, and the emerging field of inflammaging. Evidence-based therapeutic and preventive implications are discussed, with emphasis on strategies for mitigating inflammation-driven neuropsychiatric risk across the lifespan.
The Immune-Brain Interface: Mechanisms of Peripheral-To-Central Communication
Blood-Brain Barrier Permeability and Cytokine Transport
The blood-brain barrier (BBB) is a highly specialized neurovascular unit comprising endothelial cells connected by tight junctions, astrocytic end-feet, pericytes, and a surrounding extracellular matrix. Under homeostatic conditions, this interface restricts the passage of immune cells and large hydrophilic molecules, thereby protecting the CNS from systemic immune perturbations. However, inflammatory states induce dynamic changes in BBB integrity through multiple mechanisms that collectively render the CNS susceptible to peripheral immune signaling [1].
Pro-inflammatory cytokines, particularly TNF-α, IL-1β, and IL-6 upregulate endothelial expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), facilitating leukocyte trafficking across the barrier. Simultaneously, matrix metalloproteinases (MMPs) degrade tight junction proteins including claudin-5 and occludin, increasing paracellular permeability. This mechanistic cascade allows circulating cytokines, particularly those produced during systemic inflammatory episodes to enter the CNS parenchyma via saturable transport mechanisms, contributing directly to neuroinflammatory activation. Importantly, the BBB response to inflammation is bidirectional: CNS-derived signals can also modulate peripheral immune function, establishing a dynamic neuroimmune feedback loop that sustains or amplifies pathological states [1,8].
Dysregulation of BBB integrity, as observed in chronic metabolic inflammation, sepsis, traumatic brain injury, and autoimmune conditions, is now recognized as a key contributor to the neuropsychiatric comorbidities frequently observed in these disorders. Peripheral endotoxemia, elevated circulating lipopolysaccharide (LPS), arising from gut dysbiosis is a particularly relevant mechanism in metabolic disease, wherein compromised intestinal barrier function allows bacterial fragments to enter systemic circulation and subsequently cross a sensitized BBB [7,8].
Neural Pathways: The Vagus Nerve and Sympathetic Nervous System
Peripheral inflammatory signals are relayed to the brain with extraordinary speed via afferent neural pathways, preceding the slower humoral routes by several hours. The vagus nerve, the primary parasympathetic trunk innervating visceral organs, carries immunosensory information from peripheral tissues to the nucleus tractus solitarius (NTS) in the brainstem, which projects to hypothalamic and limbic regions critically implicated in immune regulation, stress responses, and behavior [9].
Perivascular macrophages and dendritic cells within peripheral tissues express cytokine receptors and release prostaglandins that activate vagal afferent neurons bearing IL-1β receptors. This neural immune surveillance mechanism enables the brain to detect peripheral inflammation within minutes and mount coordinated physiological and behavioral responses. Tracey’s landmark work further demonstrated that the vagus nerve conducts an “inflammatory reflex”, an efferent cholinergic pathway that suppresses peripheral cytokine production via nicotinic acetylcholine receptors on tissue macrophages, illustrating the therapeutic potential of vagal neuroimmune modulation. Preclinical and early clinical studies of vagal nerve stimulation for inflammatory and neuropsychiatric conditions have yielded encouraging results, with anti-inflammatory and antidepressant effects observed in treatment-refractory populations [9,10].
The sympathetic nervous system (SNS) contributes additionally to bidirectional immune-brain communication. Catecholamines released at sympathetic nerve terminals directly modulate lymphocyte and macrophage function via adrenergic receptors, while centrally released norepinephrine influences neuroinflammatory tone in regions including the locus coeruleus and prefrontal cortex. Psychosocial stress, operating via SNS and HPA axis activation, amplifies this neuroimmune interface, providing a mechanistic explanation for the well-documented relationship between chronic social stress and elevated inflammatory biomarkers [10,11].
Humoral Signaling and Circumventricular Organs
Circumventricular organs (CVOs), specialized brain regions lacking a complete BBB, including the area postrema, subfornical organ, and organum vasculosum of the lamina terminalis, serve as critical sensors for circulating cytokines, pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs). CVO neurons express toll-like receptors (TLRs), cytokine receptors, and prostaglandin receptors, enabling direct transduction of peripheral inflammatory signals into CNS neural activity without requiring BBB penetration. Activated CVO neurons relay signals to hypothalamic nuclei, where prostaglandin E2 (PGE2) and thromboxanes mediate fever induction, corticotropin-releasing hormone (CRH) release, and HPA axis activation, the central neuroendocrine cascade governing the physiological stress response. These humoral mechanisms operate in concert with the neural routes described above to produce a coordinated, multilevel neuroimmune response [11].
Neuroinflammation: Microglial Activation and Central Immune Cascades
Microglial Polarization States
Microglia, the resident macrophages of the CNS constitute approximately 10–15% of total brain cells and function as the primary effectors of innate CNS immunity. In their homeostatic state, microglia continuously survey the local microenvironment through motile processes, monitoring synaptic activity, clearing cellular debris, and pruning inappropriate synaptic connections as part of normal neurodevelopmental and maintenance functions [12].
Upon detection of inflammatory signals, whether derived from peripheral immune activation, neuronal DAMPs, or direct pathogen recognition, microglia undergo rapid morphological and functional transformation. The polarization paradigm describes at least two major activation states: the M1 pro-inflammatory phenotype, characterized by upregulation of MHC-II, CD68, iNOS, and secretion of TNF-α, IL-1β, IL-6, and reactive oxygen species (ROS); and the M2 anti-inflammatory/reparative phenotype, defined by expression of arginase-1, Ym1, and secretion of IL-10 and TGF-β. In vivo, these states exist on a dynamic spectrum, and chronic or unresolved peripheral inflammation biases microglial responses toward sustained pro-inflammatory M1 activation. Evidence from positron emission tomography (PET) using translocator protein (TSPO) ligands, validated markers of microglial activation has demonstrated elevated neuroinflammatory activity in patients with MDD, Alzheimer’s disease, and autism spectrum disorder, directly linking microglial activation to these clinical conditions [13,14].
Neuroinflammatory Mediators and Their Downstream Effects
The inflammatory cytokines released by activated microglia and infiltrating monocytes exert pleiotropic effects on brain neurochemistry and neural network function. TNF-α and IL-1β suppress hippocampal long-term potentiation (LTP), a cellular correlate of learning and memory and reduce neurogenesis in the hippocampal dentate gyrus, directly implicating neuroinflammatory cytokines in the cognitive deficits observed during inflammatory states [16].
Of particular mechanistic significance, pro-inflammatory cytokines induce the enzyme indoleamine 2,3-dioxygenase (IDO), which catabolizes tryptophan along the kynurenine pathway rather than toward serotonin synthesis. This inflammatory shunting of tryptophan metabolism yields neuroactive metabolites including quinolinic acid, an NMDA receptor agonist with excitotoxic properties and kynurenic acid, an antagonist at glutamate and α7 nicotinic receptors. The net neurochemical result includes reduced serotonergic tone, enhanced glutamate excitotoxicity, and disrupted dopaminergic reward circuitry, a profile that is remarkably congruent with the neurobiological substrates of depression, anhedonia, and cognitive impairment [15,17].
Additionally, neuroinflammation disrupts brain-derived neurotrophic factor (BDNF) signaling, a key mediator of synaptic plasticity, neuronal survival, and mood regulation. Elevated IL-6 and TNF-α suppress BDNF expression in the hippocampus and prefrontal cortex, contributing to the structural brain changes, including reduced hippocampal and prefrontal gray matter volume, documented in chronic inflammatory and depressive states. These structural and neurochemical perturbations converge to produce functionally significant impairments in memory encoding, emotional processing, and executive control [16,17].
Inflammation and Cognitive Function
Acute Inflammation and Transient Cognitive Impairment
The acute-phase response to systemic infection or injury reliably produces transient but functionally significant cognitive deficits, a phenomenon well-characterized in both experimental and clinical contexts. Experimental administration of bacterial lipopolysaccharide (LPS) to healthy human volunteers produces rapid-onset impairments in episodic memory, sustained attention, and psychomotor speed, accompanied by elevated plasma IL-6 and TNF-α levels within hours. These effects are mediated centrally through cytokine-induced reductions in hippocampal theta oscillation frequency, prefrontal dopaminergic neurotransmission, and working memory network connectivity, as assessed by functional neuroimaging [18].
Clinically, postoperative cognitive dysfunction (POCD) and intensive care unit (ICU)-acquired delirium represent paradigmatic examples of acute neuroinflammation producing functionally significant cognitive impairment. The inflammatory burden of major surgery or critical illness, combined with anaesthetic agents, hemodynamic instability, and metabolic stress generates substantial peripheral cytokine release that traverses a compromised BBB, producing microglial activation, disrupted neural oscillations, and altered neurotransmitter dynamics. POCD disproportionately affects older adults with pre-existing low-grade neuroinflammation, and its incidence correlates with the magnitude of perioperative cytokine elevations, supporting a direct inflammatory etiology [19].
Chronic Neuroinflammation and Neurodegenerative Risk
Converging longitudinal epidemiological data demonstrates that elevated circulating inflammatory markers in midlife predict accelerated cognitive decline and dementia in later years. A large population-based study found that elevated IL-6 and CRP levels at age 50 were independently associated with greater decline in memory, semantic fluency, and executive function over 10 years of follow-up, after adjustment for cardiovascular and metabolic confounders. These associations suggest that chronic low-grade inflammation, even well below the threshold of clinically overt disease exerts a cumulative erosive effect on cognitive reserve over decades [20].
Alzheimer’s disease provides the most thoroughly studied example of neuroinflammation’s contribution to neurodegenerative pathology. Amyloid-β (Aβ) plaques and neurofibrillary tau tangles activate microglia and complement cascades, generating a self-perpetuating neuroinflammatory cycle that accelerates synaptic loss, neuronal death, and cognitive decline. Genome-wide association studies (GWAS) have identified numerous immune-related risk loci for AD, including TREM2, CLU, CR1, and CD33 underscoring the genetic integration of immune dysregulation into AD pathogenesis. TREM2 variants that reduce microglial phagocytic capacity impair the clearance of Aβ and cellular debris, directly linking innate immune function to amyloid burden [5].
In Parkinson’s disease, activated microglia in the substantia nigra pars compacta release ROS and pro-inflammatory mediators that selectively damage dopaminergic neurons, contributing to the progressive motor and non-motor features of the disease. Epidemiological evidence reveals that systemic inflammatory conditions, including inflammatory bowel disease, systemic lupus erythematosus, and chronic obstructive pulmonary disease are associated with elevated PD risk, likely because sustained peripheral immune activation initiates and accelerates central neuroinflammatory cascades via the mechanisms described in Section 2 [6,8].
Inflammation, Mood, and Behavioral Disorders
Sickness Behavior: An Evolutionary Perspective
Sickness behavior, comprising fatigue, hypersomnia, anorexia, social withdrawal, reduced exploratory locomotion, anhedonia, and heightened pain sensitivity, represents an evolutionarily conserved adaptive response to infection. First systematically characterized by Dantzer and colleagues, sickness behavior is now understood to be actively organized by the brain in response to pro-inflammatory cytokine signals, rather than being a passive consequence of physiological debility. Experimental administration of IL-1β, IL-6, TNF-α, or interferon-alpha (IFN-α) reliably recapitulates the full spectrum of sickness behavior in rodent models; conversely, central or peripheral administration of cytokine antagonists attenuates these behavioral effects [2,3].
The adaptive logic of sickness behavior is biologically coherent: by redirecting metabolic resources from behavioral activity toward immune effector function, reducing nutritional intake (thereby limiting nutrient availability to replicating pathogens), and promoting rest (facilitating tissue repair and regeneration), the organism improves infection outcomes at the cost of short-term social and productive functioning. However, when the inflammatory signal becomes chronic, as occurs in autoimmune diseases, metabolic syndrome, persistent psychosocial adversity, or unresolved low-grade infection, the sustained suppression of reward-motivated behavior, social affiliation, and motivated cognition transitions from adaptive to pathological, providing a mechanistic template for neuropsychiatric comorbidity in medically ill populations [2,3].
Inflammatory Biomarkers in Major Depressive Disorder
The inflammatory hypothesis of depression has accumulated substantial empirical support over the past two decades. A landmark meta-analysis by Dowlati et al. encompassing 24 studies found significantly elevated concentrations of TNF-α and IL-6 in patients with MDD compared to healthy controls, an effect that persisted after excluding studies with high confound risk. A subsequent meta-analysis by Osimo et al. extending this analysis to 5,166 patients across diverse clinical settings confirmed elevated CRP, IL-6, and TNF-α in depression, with effect sizes robust to methodological variation and independent of antidepressant treatment status [4,22].
Inflammatory biomarkers in depression are not merely epiphenomenal; they predict treatment response and may differentiate mechanistic subtypes. Approximately one-third of patients with MDD who fail to respond to conventional antidepressants exhibit higher baseline CRP and IL-6 concentrations, implicating immune-mediated neurochemical disruptions as treatment-resistant substrates. Prospective clinical trials provide some of the most compelling causal evidence: cancer patients receiving interferon-alpha immunotherapy predictably develop a depressive syndrome, and the severity of depressive symptoms correlates with the magnitude of IFN-α-induced IDO activation and kynurenine pathway dysregulation. Furthermore, infliximab (an anti-TNF-α monoclonal antibody) reduced depressive symptoms selectively in patients with elevated baseline CRP (>5 mg/L) in a randomized placebo-controlled trial, providing proof-of-concept for inflammation-targeted antidepressant therapy in biologically stratified populations [15,17,23].
Anxiety, Stress, and HPS Axis Dysregulation
The interplay between systemic inflammation, psychosocial stress, and the HPA axis constitutes a critical regulatory circuit governing behavioral vulnerability. Acute stress activates the HPA axis, culminating in cortisol release that initially suppresses pro-inflammatory cytokine production, a glucocorticoid-mediated negative feedback mechanism ensuring proportionate and time-limited immune responses. However, chronic psychological stress induces glucocorticoid receptor resistance in peripheral immune cells, resulting in paradoxical upregulation of NF-κB-driven inflammatory gene expression despite persistently elevated cortisol [24].
The glucocorticoid resistance model, developed by Slavich, Irwin, and Miller, proposes that social threat signals, particularly social exclusion, subordination, and anticipation of physical harm, activate conserved innate immune programs via SNS activation, generating IL-6 and CRP elevations that contribute to depression vulnerability in the context of life adversity. Chronic stress-induced IL-1β and TNF-α additionally sensitize HPA axis reactivity by upregulating CRH expression in the paraventricular nucleus of the hypothalamus, creating a self-amplifying neuroimmune loop of stress–inflammation–behavioral dysfunction. Normalization of this dysregulated HPA-immune axis may represent a mechanistic target for the prevention of stress-related psychiatric sequelae in individuals with high inflammatory burden [24,25].
Anxiety disorders have received comparatively less attention in the neuroimmune literature; however, accumulating evidence implicates elevated IL-6, CRP, and IFN-γ in generalized anxiety disorder, panic disorder, and post-traumatic stress disorder (PTSD). Mechanistically, inflammatory cytokines reduce GABAergic inhibitory tone in the amygdala and increase glutamate-driven fear circuitry reactivity, neurochemical changes directly consistent with anxiety phenomenology. The bidirectional nature of this relationship is underscored by evidence that anxiety disorders independently predict future elevations in inflammatory biomarkers, suggesting that neuropsychiatric conditions may themselves perpetuate the inflammatory states that contribute to their pathogenesis [11].
The Gut-Brain-Immune Axis
The gut microbiome, comprising approximately 3.8 × 1013 microorganisms spanning bacteria, archaea, fungi, and viruses exerts extraordinary influence over both systemic immune function and CNS physiology through a bidirectional communication network designated the microbiota-gut-brain axis. The gut-associated lymphoid tissue (GALT) harbors approximately 70% of the body’s immune effector cells, positioning the intestinal microenvironment as the primary interface between the external environment and systemic immunity [21].
Dysbiosis, pathological alterations in the composition, diversity, and metabolic activity of the gut microbiota generates intestinal barrier dysfunction, colloquially termed “leaky gut,” characterized by increased translocation of LPS and bacterial fragments into the portal and systemic circulation. This phenomenon, termed metabolic endotoxemia, drives chronic low-grade systemic inflammation via TLR4 signaling on hepatic Kupffer cells and circulating monocytes, generating sustained IL-6, IL-1β, and TNF-α elevation. Metabolic endotoxemia is now recognized as a mechanistic nexus linking dietary quality, gut microbiome composition, and systemic inflammatory state [7,21].
Gut dysbiosis is robustly associated with neuropsychiatric conditions including MDD, autism spectrum disorder, Parkinson’s disease, and Alzheimer’s disease, conditions where neuroinflammation is a convergent pathological feature. The mechanisms linking gut microbiota to brain function are multiple and include: short-chain fatty acids (SCFAs) produced by microbial fermentation, which modulate microglial maturation and BBB integrity; enteric nervous system transmission of microbial signals to the brain via vagal afferents; microbially influenced synthesis of neuroactive compounds including serotonin precursors (approximately 90% of circulating serotonin is synthesized in the gut under microbial influence); and modulation of the tryptophan-kynurenine pathway [21].
Interventional studies with probiotics, prebiotics, synbiotics, and dietary modifications demonstrate modest but clinically meaningful effects on both inflammatory biomarkers and psychological outcomes, providing proof-of-principle that the gut-brain-immune axis is a viable and accessible therapeutic target. The Mediterranean dietary pattern, characterized by high consumption of polyphenol-rich plant foods, omega-3 fatty acids, and fermentable dietary fiber is independently associated with reduced systemic inflammation and lower risk of depression and cognitive decline across multiple large prospective cohorts, likely via favorable modulation of gut microbiota composition and microbially derived anti-inflammatory metabolite profiles [21,28].
Metabolic Inflammation and Brain Health: Implications for Longevity
Metaflammation and Hypothalamic Dysfunctional
The term “metaflammation”, coined by Hotamisligil describes the chronic, low-grade, tissue-resident inflammatory state driven by excess nutrient availability, adiposity, and metabolic substrate overload. Unlike acute inflammation, metaflammation is characterized by sustained activation of the NF-κB and JNK inflammatory signaling pathways in metabolically active tissues, including visceral adipose tissue, liver, skeletal muscle, pancreatic islets, and critically, the hypothalamus without the complete resolution phase that characterizes acute inflammatory episodes [7].
Hypothalamic inflammation represents a particularly consequential manifestation of metaflammation, given the hypothalamus’s central roles in energy homeostasis, neuroendocrine regulation, circadian rhythm coordination, and motivational behavior. In murine models of diet-induced obesity, activation of TLR4 and IKKβ/NF-κB in hypothalamic neurons impairs leptin and insulin receptor signaling within as little as three days of high-fat diet exposure, producing central resistance to satiety signals and perpetuating positive energy balance. This inflammatory disruption of hypothalamic neurocircuitry simultaneously dysregulates dopaminergic reward pathways, sleep-wake cycles, and HPA axis function, generating behavioral sequelae including compulsive feeding, reduced motivation for non-food rewards, emotional lability, and impaired prefrontal executive control [7,27].
These findings carry important clinical implications: individuals with metabolic syndrome, obesity, or type 2 diabetes, conditions defined by metaflammation exhibit significantly elevated rates of depression, anxiety, cognitive impairment, and dementia risk. The neuroimmune mechanisms described in this review provide a biologically coherent explanatory framework for these comorbidities, and suggest that metabolic optimization strategies may yield concomitant neuropsychiatric benefits via reduction of inflammatory burden at the gut-hypothalamic interface [3,7].
Inflammaging and Cognitive Reserve
Inflammaging, the chronic, sterile, low-grade systemic inflammatory state that characterizes normal biological aging represents a convergence of metabolic, immunological, and environmental factors that cumulatively impair CNS homeostasis over the lifespan. As individuals age, the immune system undergoes “immunosenescence”, a progressive decline in adaptive immune function accompanied by paradoxical innate immune hyperactivation, yielding persistently elevated IL-6, TNF-α, and CRP even in the absence of overt infection or injury. Contributing factors include the accumulation of senescent cells secreting the senescence-associated secretory phenotype (SASP), chronic viral reactivation (particularly CMV and EBV), gut microbiome compositional shifts favoring pro-inflammatory taxa, and progressive mitochondrial dysfunction generating increased cellular ROS [26].
Inflammaging is mechanistically linked to reduced cognitive reserve through multiple converging pathways: accelerated microglial priming rendering aged microglia hyperreactive and disproportionately responsive to secondary stimuli; progressive synaptic loss driven by complement-mediated synapse elimination; impaired resolution of neuroinflammatory episodes due to reduced synthesis of specialized pro-resolving mediators (SPMs) including resolvins, protectins, and maresins; and accumulation of oxidative damage to neuronal DNA and mitochondria. Longitudinal studies demonstrate that composite inflammatory indices, incorporating CRP, IL-6, and fibrinogen, independently predict the rate of cognitive decline, hippocampal atrophy, and conversion from mild cognitive impairment (MCI) to clinically diagnosed dementia [20,26].
From a longevity medicine perspective, attenuating the inflammaging trajectory represents a high-leverage strategy for extending cognitive health span. The concept of a “low inflammatory phenotype” as a predictor of exceptional longevity is supported by studies of centenarians, who demonstrate paradoxically preserved anti-inflammatory regulatory capacity alongside age-appropriate innate immune activation, suggesting that the balance, rather than the mere absence of inflammatory activity determines neurocognitive aging trajectories [26].
Therapeutic and Preventive Strategies
The mechanistic understanding of inflammation-brain interactions reviewed above has generated a rich landscape of therapeutic targets, spanning pharmacological, nutritional, lifestyle-based, and microbiome-directed interventions. A systematic review and meta-analysis by Köhler et al. evaluating 14 randomized controlled trials of anti-inflammatory treatments in patients with depression found significant reductions in depressive symptom scores compared to placebo, with particularly robust effects in subgroups with elevated baseline inflammatory markers. These findings provide strong clinical evidence supporting inflammation-stratified patient selection for anti-inflammatory augmentation strategies [23].
Pharmacological approaches include selective COX-2 inhibitors (e.g., celecoxib), cytokine antagonists (infliximab targeting TNF-α; tocilizumab targeting IL-6 receptor), and low-dose minocycline, a tetracycline antibiotic with potent microglial suppression properties that has demonstrated antidepressant activity in early-phase clinical trials. Each approach carries therapeutic promise alongside important limitations, including immunosuppressive side effects, infection risk, and the need for robust biomarker-based patient stratification to optimize benefit-risk ratios [17,23].
Lifestyle-based interventions occupy a central and evidence-supported position in inflammation-directed neuropsychiatric care. Regular moderate-intensity aerobic exercise robustly reduces circulating IL-6, TNF-α, and CRP while upregulating anti-inflammatory IL-10, BDNF, and adiponectin, producing both peripheral anti-inflammatory and direct central neuroprotective effects. Exercise-induced myokines, including IL-6 transiently released from contracting skeletal muscle in an anti-inflammatory context, stimulate downstream production of IL-1 receptor antagonist (IL-1Ra) and IL-10, generating a post-exercise anti-inflammatory milieu distinct from the pathological IL-6 elevation seen in metabolic disease [26].
Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce NF-κB transcriptional activity, promote the synthesis of SPMs, and modulate microglial function toward anti-inflammatory phenotypes. Meta-analyses indicate antidepressant effects of EPA supplementation, with greatest efficacy in patients with elevated inflammatory biomarkers or concurrent metabolic comorbidities. Sleep optimization, mindfulness-based stress reduction, and targeted correction of gut dysbiosis through dietary fiber enrichment, fermented food consumption, and clinically indicated probiotic supplementation represent additional evidence-supported pillars of a comprehensive anti-inflammatory neuro-behavioural strategy [21,28].
Emerging precision medicine approaches seek to stratify patients by inflammatory phenotype using circulating cytokine panels, high-sensitivity CRP, kynurenine-to-tryptophan ratios, and microbiome profiling, to identify individuals most likely to benefit from specific anti-inflammatory interventions, moving toward individualized neuroimmune treatment paradigms that transcend the one-size-fits-all approach of conventional neuropsychiatry [17].
Conclusion
The evidence reviewed in this paper establishes systemic inflammation as a powerful and multifaceted modulator of brain function and behavior, operating through interconnected molecular, cellular, and neural mechanisms that span from the intestinal microenvironment to hypothalamic neurocircuitry. From the immediate cognitive impairment induced by acute cytokine surges to the insidious neuropsychiatric erosion imposed by metaflammation and inflammaging, the immune-brain interface represents a critical regulatory nexus at the intersection of physical and mental health.
The convergence of neuroinflammation in the pathophysiology of depression, anxiety, cognitive decline, and neurodegeneration has profound nosological and therapeutic implications: conditions once perceived as categorically distinct may share common immune-driven mechanisms amenable to shared and overlapping treatment approaches. For clinicians and researchers in longevity medicine and metabolic health, these findings underscore the imperative to assess and address inflammatory burden not merely as a cardiovascular or metabolic risk factor, but as a central and modifiable determinant of neuropsychiatric health across the lifespan.
Inflammatory biomarker profiling, gut microbiome assessment, and systematic evaluation of neuroimmune risk factors including dietary quality, sleep architecture, physical activity, psychosocial adversity, and visceral adiposity should be incorporated into comprehensive health optimization protocols. Conversely, interventions that measurably reduce systemic inflammation hold promise not only for metabolic endpoints but for the preservation of cognitive vitality, emotional resilience, and behavioral health into advanced age.
Future research priorities include the development and clinical validation of composite neuroimmune biomarker panels for risk stratification, well-powered randomized trials of anti-inflammatory interventions in neuropsychiatrically defined patient cohorts, and mechanistic dissection of the individual differences in immune-to-brain signaling, including contributions from sex hormones, genetic polymorphisms in cytokine and innate immune genes, epigenetic programming of microglial function by early life adversity, and diet-microbiome interactions. The brain and the immune system, once conceived as operationally independent, are now understood to be profoundly and reciprocally intertwined and this integration holds transformative implications for our understanding of mental health, cognitive aging, and the biological determinants of human longevity.
Reference
1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
2. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
3. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15(1):7-24.
4. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-57.
5. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388-405.
6. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37(3):510-8.
7. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-85.
8. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777-83.
9. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-9.
10. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37(1):137-62.
11. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226-38.
12. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441-68.
13. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69.
14. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268-75.
15. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31.
16. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25(2):181-213.
17. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23-34.
18. Krabbe KS, Reichenberg A, Yirmiya R, Moller K, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun. 2005;19(5):453-60.
19. Skvarc DR, Berk M, Byrne LK, Dean OM, Dodd S, Lewis M, et al. Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapeutic targets. Neurosci Biobehav Rev. 2018;84:116-33.
20. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al. Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology. 2014;83(6):486-93.
21. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013.
22. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-9.
23. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, cognitive function, and quality of life in patients with depression: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-91.
24. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014;140(3):774-815.
25. Liu YN, Peng YL, Liu L, Wu TY, Zhang Y, Lian YJ, et al. TNFalpha mediates stress-induced depression by sensitizing neuronal hypothalamic-pituitary-adrenal axis function. Brain Behav Immun. 2015;43:159-66.
26. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-90.
27. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61-73.
28. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-15.
29. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83(5):495-502.
30. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.